Table 1.
Clinical characteristics of the study cohort (n = 9)
| Mean agea, years (range) | 64.2 (51–74) |
| Gleason score at diagnosisb, n (%) | |
| 7 (3 + 4) | 5 (55.6) |
| 9 | 4 (44.4) |
| Metastatic sites, n (%) | |
| Bone | 9 (100) |
| Lymph node | 2 (22.2) |
| Evidence of castration resistance at recruitment (cohort)c, n (%) | |
| No (mPCa; cohort 1) | 5 (55.6) |
| Yes (mCRPC; cohort 2) | 4 (44.4) |
| Number of timepointsd, n (%) | |
| 4 | 2 (22.2) |
| 5 | 2 (22.2) |
| 6 | 5 (55.6) |
| Mean cfDNA concentratione, ng/ul (range) | 5.08 (0.61–38) |
| Mean PSA levelse, ng/ml (range) | 35.3 (0.1–352.1) |
| Therapies administeredf, n (%) | |
| LHRH agonists/antagonists | 8 (88.9) |
| Taxanes | 9 (100) |
| AR-inhibitors | 8 (88.9) |
| Radioisotopes | 3 (33.3) |
| Mean follow-up timeg, months (range) | 19.1 (13–21) |
AR androgen receptor, cfDNA cell-free DNA, LHRH Luteinizing hormone-releasing hormone, mPCa metastatic prostate cancer, mCRPC metastatic castration resistant prostate cancer, PSA prostate-specific antigen
Other notes: aAge at time of recruitment
bPrior to recruitment
cCohort classification: Cohort 1—patient was on/starting androgen deprivation therapy at time of recruitment, and had no evidence of castration resistance; Cohort 2—patient had castration resistant disease at time of recruitment
dTimepoint refers to number of cfDNA isolations available for study
eAt any given timepoint
fDuring follow-up in the iPROSPECT study
gFollow-up time reflects last timepoint obtained for this analysis